Transtympanic gentamicin for Meniere's syndrome

Stephen G. Harner, Jan Kasperbauer, George W. Facer, Charles W. Beatty

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objectives: Study the impact of transtympanic gentamicin on patients with unilateral Meniere's syndrome. Partial chemical labyrinthectomy is a relatively recent concept for the treatment of Meniere's syndrome. It uses the ototoxic effect of gentamicin to reduce the symptom of vertigo and maintain cochlear function. Study Design: A prospective study using transtympanic gentamicin was begun in January 1994. Patients selected had failed medical therapy, but were not incapacitated. Patients had preinjection audiometric and electronystagmography data. Most had an imaging study. All had one injection, about half had more than one. Patients were seen 1 month after therapy and repeat studies were obtained. Repeat injection was performed if indicated. Follow-up from the chart or by telephone was obtained. Data were tabulated using the 1995 American Academy of Otologaryngology-Head and Neck Surgery guidelines. Results: Through December 1996 43 patients with unilateral Meniere's syndrome were treated. The pretherapy function level was 3 through 5. After therapy the function level was 1 or 2. There was almost no change in cochlear function and no patient became deaf. Many patients had mild ataxia or dysequilibrium during the first 2 weeks following therapy. Most patients showed some decrease in labyrinthine function measured on electronystagmography. No attempt was made to ablate labyrinthine function. Seventeen of 18 patients had a vertigo index in the class A or B category after 2 years. Conclusions: Transtympanic gentamicin has become the treatment of choice for patients who fail medical therapy for Meniere's syndrome at the authors' institution.

Original languageEnglish (US)
Pages (from-to)1446-1449
Number of pages4
JournalLaryngoscope
Volume108
Issue number10
DOIs
StatePublished - Oct 1 1998

Fingerprint

Meniere Disease
Gentamicins
Electronystagmography
Cochlea
Vertigo
Therapeutics
Injections
Ataxia
Telephone
Neck
Head
Prospective Studies
Guidelines

Keywords

  • Chemical labyrinthectomy
  • Gentamicin
  • Meniere's syndrome
  • Transtympanic gentamicin

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Transtympanic gentamicin for Meniere's syndrome. / Harner, Stephen G.; Kasperbauer, Jan; Facer, George W.; Beatty, Charles W.

In: Laryngoscope, Vol. 108, No. 10, 01.10.1998, p. 1446-1449.

Research output: Contribution to journalArticle

Harner, Stephen G. ; Kasperbauer, Jan ; Facer, George W. ; Beatty, Charles W. / Transtympanic gentamicin for Meniere's syndrome. In: Laryngoscope. 1998 ; Vol. 108, No. 10. pp. 1446-1449.
@article{db144726213641d58a57e94e1d44f5b4,
title = "Transtympanic gentamicin for Meniere's syndrome",
abstract = "Objectives: Study the impact of transtympanic gentamicin on patients with unilateral Meniere's syndrome. Partial chemical labyrinthectomy is a relatively recent concept for the treatment of Meniere's syndrome. It uses the ototoxic effect of gentamicin to reduce the symptom of vertigo and maintain cochlear function. Study Design: A prospective study using transtympanic gentamicin was begun in January 1994. Patients selected had failed medical therapy, but were not incapacitated. Patients had preinjection audiometric and electronystagmography data. Most had an imaging study. All had one injection, about half had more than one. Patients were seen 1 month after therapy and repeat studies were obtained. Repeat injection was performed if indicated. Follow-up from the chart or by telephone was obtained. Data were tabulated using the 1995 American Academy of Otologaryngology-Head and Neck Surgery guidelines. Results: Through December 1996 43 patients with unilateral Meniere's syndrome were treated. The pretherapy function level was 3 through 5. After therapy the function level was 1 or 2. There was almost no change in cochlear function and no patient became deaf. Many patients had mild ataxia or dysequilibrium during the first 2 weeks following therapy. Most patients showed some decrease in labyrinthine function measured on electronystagmography. No attempt was made to ablate labyrinthine function. Seventeen of 18 patients had a vertigo index in the class A or B category after 2 years. Conclusions: Transtympanic gentamicin has become the treatment of choice for patients who fail medical therapy for Meniere's syndrome at the authors' institution.",
keywords = "Chemical labyrinthectomy, Gentamicin, Meniere's syndrome, Transtympanic gentamicin",
author = "Harner, {Stephen G.} and Jan Kasperbauer and Facer, {George W.} and Beatty, {Charles W.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1097/00005537-199810000-00005",
language = "English (US)",
volume = "108",
pages = "1446--1449",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Transtympanic gentamicin for Meniere's syndrome

AU - Harner, Stephen G.

AU - Kasperbauer, Jan

AU - Facer, George W.

AU - Beatty, Charles W.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Objectives: Study the impact of transtympanic gentamicin on patients with unilateral Meniere's syndrome. Partial chemical labyrinthectomy is a relatively recent concept for the treatment of Meniere's syndrome. It uses the ototoxic effect of gentamicin to reduce the symptom of vertigo and maintain cochlear function. Study Design: A prospective study using transtympanic gentamicin was begun in January 1994. Patients selected had failed medical therapy, but were not incapacitated. Patients had preinjection audiometric and electronystagmography data. Most had an imaging study. All had one injection, about half had more than one. Patients were seen 1 month after therapy and repeat studies were obtained. Repeat injection was performed if indicated. Follow-up from the chart or by telephone was obtained. Data were tabulated using the 1995 American Academy of Otologaryngology-Head and Neck Surgery guidelines. Results: Through December 1996 43 patients with unilateral Meniere's syndrome were treated. The pretherapy function level was 3 through 5. After therapy the function level was 1 or 2. There was almost no change in cochlear function and no patient became deaf. Many patients had mild ataxia or dysequilibrium during the first 2 weeks following therapy. Most patients showed some decrease in labyrinthine function measured on electronystagmography. No attempt was made to ablate labyrinthine function. Seventeen of 18 patients had a vertigo index in the class A or B category after 2 years. Conclusions: Transtympanic gentamicin has become the treatment of choice for patients who fail medical therapy for Meniere's syndrome at the authors' institution.

AB - Objectives: Study the impact of transtympanic gentamicin on patients with unilateral Meniere's syndrome. Partial chemical labyrinthectomy is a relatively recent concept for the treatment of Meniere's syndrome. It uses the ototoxic effect of gentamicin to reduce the symptom of vertigo and maintain cochlear function. Study Design: A prospective study using transtympanic gentamicin was begun in January 1994. Patients selected had failed medical therapy, but were not incapacitated. Patients had preinjection audiometric and electronystagmography data. Most had an imaging study. All had one injection, about half had more than one. Patients were seen 1 month after therapy and repeat studies were obtained. Repeat injection was performed if indicated. Follow-up from the chart or by telephone was obtained. Data were tabulated using the 1995 American Academy of Otologaryngology-Head and Neck Surgery guidelines. Results: Through December 1996 43 patients with unilateral Meniere's syndrome were treated. The pretherapy function level was 3 through 5. After therapy the function level was 1 or 2. There was almost no change in cochlear function and no patient became deaf. Many patients had mild ataxia or dysequilibrium during the first 2 weeks following therapy. Most patients showed some decrease in labyrinthine function measured on electronystagmography. No attempt was made to ablate labyrinthine function. Seventeen of 18 patients had a vertigo index in the class A or B category after 2 years. Conclusions: Transtympanic gentamicin has become the treatment of choice for patients who fail medical therapy for Meniere's syndrome at the authors' institution.

KW - Chemical labyrinthectomy

KW - Gentamicin

KW - Meniere's syndrome

KW - Transtympanic gentamicin

UR - http://www.scopus.com/inward/record.url?scp=0031682639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031682639&partnerID=8YFLogxK

U2 - 10.1097/00005537-199810000-00005

DO - 10.1097/00005537-199810000-00005

M3 - Article

C2 - 9778281

AN - SCOPUS:0031682639

VL - 108

SP - 1446

EP - 1449

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 10

ER -